Spero Therapeutics, Inc.
Nasdaq · Healthcare · Pharmaceutical Preparations · Cambridge, MA
SPRO chart
What traders are saying about $SPRO
Latest postsSpero Therapeutics, Inc. news
- SPRO Q3'26 Earnings: revenue estimate is 0 USD
TradingView ·
- Spero Therapeutics, Inc. expected to post a loss of 47 cents a share - Earnings Preview
TradingView ·
- Alphabet maintains massive SpaceX bet, initiates $548M Qualcomm stake
TradingView ·
- Spero Therapeutics Inc (2HA.MU) Seasonal returns chart - Yahoo Finance
Yahoo Finance Singapore ·
- Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Yahoo Finance ·
- Spero Therapeutics, Inc. (SPRO) Seasonal returns chart - Yahoo Finance
Yahoo Finance Singapore ·
- Spero Therapeutics to Present at Investor Conferences in November
Yahoo Finance ·
- Spero Therapeutics Strengthens Leadership Team to Advance Immunology Pipeline
Yahoo Finance ·
- Spero Therapeutics Targets 2027 Phase II Launch for SP001 in IgG4-Related Disease
marketbeat.com ·
- Spero Therapeutics to Participate in the Chardan 10th Annual Healthcare Conference
Yahoo Finance ·
- Complicated Urinary Tract Infections Market Set for Expansion by 2036, Supported by Recent Drug Approvals Including GSK/Spero Therapeutics’ UTEBZI and Wockhardt’s ZAYNICH and Emerging Therapies | DelveInsight
Yahoo Finance ·
- Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Yahoo Finance ·
Spero Therapeutics, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $12.6M | $371,000 | $933,000 | $2.5M |
| Net income | $8.6M | -$68.6M | $22.8M | – |
| Diluted EPS | $0.15 | $-1.27 | $0.43 | $-1.23 |
| Total assets (year end) | $68.9M | $110.5M | $182.4M | $124.8M |
| Cash and equivalents (year end) | $40.3M | $52.9M | $76.3M | $109.1M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Spero Therapeutics, Inc.
- Ticker
- SPRO (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- Cambridge, MA
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1701108
- Former names
- Spero Therapeutics, LLC
Frequently asked questions
What exchange is Spero Therapeutics, Inc. listed on?
Spero Therapeutics, Inc. trades on the Nasdaq under the ticker symbol SPRO.
What industry is Spero Therapeutics, Inc. in?
Spero Therapeutics, Inc. is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Spero Therapeutics, Inc. headquartered?
Spero Therapeutics, Inc.'s business address on file with the SEC is in Cambridge, MA.
When does Spero Therapeutics, Inc.'s fiscal year end?
Spero Therapeutics, Inc.'s fiscal year ends on December 31.
How much revenue did Spero Therapeutics, Inc. report?
Spero Therapeutics, Inc. reported $12.6M in revenue for calendar year 2025, according to its SEC filings.